| Company name | ABIOMED, Inc. |
| Stock ticker | ABMD |
| Live stock price | [stckqut]ABMD[/stckqut] |
| P/E compared to competitors | Good |
MANAGEMENT EXECUTION
| Employee productivity | Good |
| Sales growth | Good |
| EPS growth | Good |
| P/E growth | Good |
| EBIT growth | Good |
| Price growth | Good |
| R&D growth | Good |
| Income growth | Good |
| Assets growth | Good |
| Return on Assets growth | Good |
| Income / Rev growth | Good |
| TWCA Plus | Good |
| Standard TWCA | Good |
| Weighted ann. stock price increase | Good |
ANALYSIS
| Confident Investor Rating | Good |
| Target stock price (TWCA growth scenario) | $356.33 |
| Target stock price (averages with growth) | $1250.69 |
| Target stock price (averages with no growth) | $346.48 |
| Target stock price (manual assumptions) | $355.92 |
The following company description is from Reuters: https://finance.yahoo.com/quote/abmd/profile?p=abmd
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company engages in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in ABIOMED, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable. It is quite rare for any company to receive a Good rating in all of my measurements above, this company is currently one of the best out there, in my opinion
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.
How was this analysis of ABIOMED, Inc. calculated?
For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:
- Stock price at the time of the calculation: $230.66
- Growth: 0.2
- Current EPS (TTM): $4.43
- P/E: 52
- Future EPS Calc: $11.02
- Future Stock Price Calc: $573.2
- Target stock price: $355.91
[/s2If]
I hope that this makes you a Confident Investor.